Bayer acquires cancer drugs rights from Loxo | FDA approves Abilify pills embedded with digital tracker | Novartis, Homology to collaborate on eye, blood disorder studies
November 16, 2017
Aon Life Sciences Advisor
SIGN UP ⋅   FORWARD
Top Stories
Bayer acquires cancer drugs rights from Loxo
Loxo Oncology granted Bayer development and global commercialization rights to cancer candidates LOXO-101, or larotrectinib, for adult and pediatric patients with unresectable or metastatic solid tumors with NTRK-fusion proteins, and LOXO-195, which is in Phase I/II trial for patients with cancers that have acquired resistance to initial tropomyosin receptor kinase treatment. The deal gives Loxo $400 million upfront and $1.2 billion in milestones, plus royalties.
BioCentury (11/14) 
LinkedIn Twitter Facebook Google+ Email
FDA approves Abilify pills embedded with digital tracker
The FDA approved a formulation of Otsuka Pharmaceutical's mental health drug Abilify that contains a tracking device developed by Proteus Digital Health. The device is activated by stomach juices and sends a signal to a wearable patch, which transmits data to a smartphone application, in an effort to help with medication regimen compliance.
Reuters (11/14) 
LinkedIn Twitter Facebook Google+ Email
Other News
Liability and Safety
Juno presents analysis behind CAR-T trial deaths because of cerebral edema
Juno Therapeutics presented a report at the Society for Immunotherapy of Cancer conference last week discussing its findings on the deaths of five patients with advanced acute lymphoblastic leukemia that occurred during the clinical trial for the company's chimeric antigen receptor T-cell therapy candidate. The report indicated that the deceased patients, who already had higher-than-average levels of the inflammatory cytokine IL-15 before infusion, experienced even higher IL-15 numbers after the treatment, causing severe brain swelling and death.
Xconomy (11/10) 
LinkedIn Twitter Facebook Google+ Email
Medtech industry uses multistakeholder approach to cybersecurity, expert says
The medical device industry's strategy to ensure cybersecurity of its products involves collaboration with regulatory agencies, health care providers, industry partners and other stakeholders to address security loopholes while raising the standards of security for all stakeholders, writes AdvaMed President and CEO Scott Whitaker. In addition to following cybersecurity regulations, the medical device industry has also established an information sharing and analysis organization and has adopted its own cybersecurity principles to help manufacturers develop cybersecurity programs based on FDA guidance and other best available information, he writes.
Morning Consult (11/14) 
LinkedIn Twitter Facebook Google+ Email
Other News
Business and Market Trends
AstraZeneca's asthma drug wins FDA nod
AstraZeneca's Fasenra, or benralizumab, was approved by the FDA as an add-on maintenance treatment for severe eosinophilic asthma in patients at least 12 years old. The company intends to market the drug in the next several weeks.
Seeking Alpha (free registration) (11/14) 
LinkedIn Twitter Facebook Google+ Email
Other News
Government and Regulatory
Health Care and Policy
Former Lilly exec gets Trump's nomination for HHS secretary
President Donald Trump announced Monday that he is nominating Alex Azar, a former Eli Lilly and Co. executive and HHS deputy secretary during President George W. Bush's administration, to serve as the next HHS secretary. The nomination was praised by Republican lawmakers, as well as industry trade groups AHIP and PhRMA, but several Democrats and health policy experts questioned Azar's ties to the pharmaceutical sector and raised concerns on whether he can fairly implement measures to lower pharmaceutical profits.
Reuters (11/13),  The Washington Post (tiered subscription model) (11/13) 
LinkedIn Twitter Facebook Google+ Email
Other News
News from Aon
Wish you were here? VR, AI and the new world of work
Immersive experiences can recreate almost any environment or workplace, and artificial intelligence can help find the best candidates from thousands of job applicants. With respondents to Aon's 2017 Global Risk Management Survey citing "disruptive technologies/innovation" such as virtual reality and AI as an "emerging risk" -- one predicted to be in the top 10 list of risks in just a few years -- it becomes clearer that forward thinking about how best to use these technologies is a growing priority for business leaders. How are VR and AI helping transform our world of work? Read more.
LinkedIn Twitter Facebook Google+ Email
2017 Aon Risk Maturity Index Insight report uncovers new insights on relationship of risk maturity and financial success
Aon Global Risk Consulting, the risk consulting business of Aon, in collaboration with the Wharton School of the University of Pennsylvania, has released its fifth edition of the Aon Risk Maturity Index Insight Report, or RMI. Report findings reinforce previous RMI research, which reveals a direct relationship between strong risk management practices and superior operating performance for organizations. New this year, the report uncovered a relationship between improved Directors and Officers premiums and risk maturity. Download the report.
LinkedIn Twitter Facebook Google+ Email
  
  
Imagination is the air of mind.
Philip James Bailey,
poet
LinkedIn Twitter Facebook Google+ Email
  
  
Learn more about Aon Life Sciences:
Aon Home Page | Aon Life Sciences
Thought Leadership | Media Room
About Aon Life Sciences Practice
Aon provides Life Sciences companies with end-to-end risk solutions, supporting organizations from the initial discovery phase to final product launch. The practice provides solutions across the Life Sciences for pharmaceutical manufacturers; generic and OTC pharmaceutical companies; biotechnology and biopharmaceutical companies; genomic and proteomic companies; drug delivery system; diagnostic substance companies; and medical device and equipment manufacturers.

Contact Aon
Aon Risk Solutions – Life Sciences
James Walters, Global Practice Leader
+1.215.255.1795
james.walters@aon.com
www.aon.com

 Linkedin Twitter
About Aon
Aon plc (NYSE:AON) is a leading global professional services firm providing a broad range of risk, retirement and health solutions. Our 50,000 colleagues in 120 countries empower results for clients by using proprietary data and analytics to deliver insights that reduce volatility and improve performance.
Powered By SmartBrief
Subscriber Tools:
Contact Us:
Editor  -  Tara Rosenzweig
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information